Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The ...

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...

Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection.  Wegovy (semaglutide) is currently approved in ...